Navigation Links
Arecor Appoints Dr. Sarah Howell as Chief Operating Officer

CAMBRIDGE, England, November 10, 2011 /PRNewswire/ --

Arecor, the leading company in advancing aqueous formulation solutions for proteins, peptides and vaccines, is pleased to announce the appointment of Dr Sarah Howell as Chief Operating Officer.  Dr Howell will be responsible for the operations of Arecor, with a focus on developing and maintaining Arecor's upward growth curve ensuring the company continues to deliver exceptional formulation solutions and performance to the highest standards across the industry.

Dr Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of products and therapeutic areas having worked in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had responsibility for CMC development and supply across BTG's diverse portfolio of products.  Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline.  She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.  Dr Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.

Tom Saylor, CEO of Arecor stated "Sarah's considerable technical and leadership experience in the management of development programmes for biologic drugs, and her capabilities in building partnerships with major pharmaceutical companies will be a tremendous asset to Arecor as it expands its business in an industry looking to formulation as an enabling technology for the new generation of biologic drugs."

Arecor was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics.  Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products.  Arecor has developed Arestat™, a patented set of tools for stabilization which address the main pathways of degradation.  As a simple reformulation, Arestat™ can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines.


Tom Saylor, CEO
Arecor Ltd
2 Cambridge Science Park
Cambridge, UK

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board
2. NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer
3. Virobay Appoints David B. Karpf, M.D. as Chief Medicial Officer
4. Axia Value Chain Appoints John Christina Managing Director of Life Sciences Practice
5. Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors
6. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
7. Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
8. Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory
9. China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee
10. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
11. Amgen Appoints Robert A. Bradway to the Companys Board of Directors
Post Your Comments:
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/29/2015)... , October 29, 2015 ... biometric authentication company focused on the growing mobile ... wallet announces that StackCommerce, a leading marketplace to ... featuring the Wocket® smart wallet on StackSocial for ... ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):